Latest Neurometrix Inc (NURO) Headlines
NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan
Business Wire - Tue Mar 11, 1:45PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat DPNCheck(R) in Japan. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
NeuroMetrix CEO Dr. Shai N. Gozani Interviewed Live on TuDiabetes.org
Business Wire - Fri Mar 07, 12:33PM CST
Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the TuDiabetes.org website yesterday, March 6, 2014. TuDiabetes.org is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.
NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy
Business Wire - Mon Mar 03, 11:08AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. The study by Lee and colleagues titled "Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy" is available at:
NeuroMetrix Reports Q4 and Full Year 2013 Results
Business Wire - Thu Feb 13, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported business and financial highlights for the fourth quarter and year ended December 31, 2013.
NeuroMetrix, Inc. Announces Date for 2013 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Wed Feb 05, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of the market on February 13, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on February 13, 2014 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global
Business Wire - Tue Feb 04, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone.
NeuroMetrix Launches www.DPNCheck.com To Support Growing NC-stat DPNCheck Business
Business Wire - Mon Jan 27, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the growing domestic and international DPNCheck(R) business. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life.
NeuroMetrix and SENSUS Pain Management System Spotlighted in Several Media Outlets
Business Wire - Wed Jan 22, 12:21PM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to five million people in the U.S. alone.
Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board
Business Wire - Thu Jan 16, 10:25AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan.
NeuroMetrix Previews Selected Highlights of Q4 2013
Business Wire - Mon Jan 13, 5:59AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013.
Stock to Watch: Neurometrix Up 19.0% (NURO)
Comtex SmarTrend(R) - Tue Dec 10, 10:12AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 19.0% to $3.57 on 5.8x average daily volume. Thus far today, Neurometrix has traded 6.2 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (19.0% to the Dow's -0.2%) and outperformed the S&P 500 (19.0% to the S&P's -0.1%) during today's trading.
NeuroMetrix to Partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China
Business Wire - Tue Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat(R) DPNCheck(R) in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.
NeuroMetrix to Present at 7th Annual OneMedForum: Investing in Healthcare 2014
Business Wire - Wed Dec 04, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), www.SENSUSRx.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 7th Annual OneMedForum at The Westin San Francisco Market Street, San Francisco, CA on January 13-15, 2014. Dr. Gozani intends to provide an update on the Company's business activities and on its diabetes products including the SENSUS(TM) pain management device for relief of chronic intractable pain, including pain associated with diabetic neuropathy, and NC-stat(R) DPNCheck(R), a diagnostic test for diabetic peripheral neuropathy.
NeuroMetrix Launches www.SENSUSRx.com
Business Wire - Fri Nov 22, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced the launch of www.SENSUSRx.com. The website provides patients and physicians with a one-stop location for information about chronic pain such as painful diabetic neuropathy and the SENSUS(TM) Pain Management System. Traditional corporate website content such as investor relations and corporate governance is also accessible.
CSCO, GCVRZ, CDW and NURO added to NASDAQ Active Stock Watch List at EPR
ACCESSWIRE - Thu Nov 14, 9:15AM CST
New York, NY - (ACCESSWIRE) - 11/14/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Cisco Systems, Inc. (NASDAQ:CSCO), Sanofi (NASDAQ:GCVRZ), CDW Corporation (NASDAQ:CDW) and NeuroMetrix Inc. (NASDAQ:NURO)
Hot Stock: Neurometrix, Shares Gain 13.6% (NURO)
Comtex SmarTrend(R) - Wed Nov 13, 10:13AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 13.6% to $2.42 on 5.3x average daily volume. Thus far today, Neurometrix has traded 2.5 million shares, vs. average volume of 475,000 shares per day. The stock has outperformed the Dow (13.6% to the Dow's -0.4%) and outperformed the S&P 500 (13.6% to the S&P's -0.1%) during today's trading.
Healthcare Companies Report Financial Results, Scheduled Presentations, Marketing Clearance and Recognitions - Research Report on Air Methods, NeuroMetrix, Quintiles, Auxilium, and Cynosure
PR Newswire - Tue Nov 12, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Air Methods Corp. (NASDAQ: AIRM), NeuroMetrix Inc. (NASDAQ: NURO), Quintiles Transnational Holdings Inc. (NYSE: Q), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), and Cynosure, Inc. (NASDAQ: CYNO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
Business Wire - Thu Nov 07, 1:02PM CST
NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology & Diagnostics Forum at The Westin Grand Central, New York, NY on November 14, 2013. Dr. Gozani intends to provide an update on the Company's business activities with particular emphasis on its SENSUS(TM) pain management system for relief of chronic intractable pain, including pain associated with diabetic neuropathy.
SmallCapReview.com - Penny Stocks On The Move - NURO, MATR
M2 - Thu Nov 07, 11:35AM CST
NeuroMetrix (NASDAQ: NURO) Trading at $2.42, Up $0.50. Today reported business and financial highlights for the third quarter ended September 30, 2013.
NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan
Business Wire - Tue Mar 11, 1:45PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat DPNCheck(R) in Japan. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
NeuroMetrix CEO Dr. Shai N. Gozani Interviewed Live on TuDiabetes.org
Business Wire - Fri Mar 07, 12:33PM CST
Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the TuDiabetes.org website yesterday, March 6, 2014. TuDiabetes.org is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.
NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy
Business Wire - Mon Mar 03, 11:08AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. The study by Lee and colleagues titled "Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy" is available at:
NeuroMetrix Reports Q4 and Full Year 2013 Results
Business Wire - Thu Feb 13, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported business and financial highlights for the fourth quarter and year ended December 31, 2013.
NeuroMetrix, Inc. Announces Date for 2013 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Wed Feb 05, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of the market on February 13, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on February 13, 2014 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global
Business Wire - Tue Feb 04, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone.
NeuroMetrix Launches www.DPNCheck.com To Support Growing NC-stat DPNCheck Business
Business Wire - Mon Jan 27, 6:00AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the growing domestic and international DPNCheck(R) business. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life.
NeuroMetrix and SENSUS Pain Management System Spotlighted in Several Media Outlets
Business Wire - Wed Jan 22, 12:21PM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to five million people in the U.S. alone.
Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board
Business Wire - Thu Jan 16, 10:25AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan.
NeuroMetrix Previews Selected Highlights of Q4 2013
Business Wire - Mon Jan 13, 5:59AM CST
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013.
Stock to Watch: Neurometrix Up 19.0% (NURO)
Comtex SmarTrend(R) - Tue Dec 10, 10:12AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 19.0% to $3.57 on 5.8x average daily volume. Thus far today, Neurometrix has traded 6.2 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (19.0% to the Dow's -0.2%) and outperformed the S&P 500 (19.0% to the S&P's -0.1%) during today's trading.
NeuroMetrix to Partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China
Business Wire - Tue Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat(R) DPNCheck(R) in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.
NeuroMetrix to Present at 7th Annual OneMedForum: Investing in Healthcare 2014
Business Wire - Wed Dec 04, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), www.SENSUSRx.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 7th Annual OneMedForum at The Westin San Francisco Market Street, San Francisco, CA on January 13-15, 2014. Dr. Gozani intends to provide an update on the Company's business activities and on its diabetes products including the SENSUS(TM) pain management device for relief of chronic intractable pain, including pain associated with diabetic neuropathy, and NC-stat(R) DPNCheck(R), a diagnostic test for diabetic peripheral neuropathy.
NeuroMetrix Launches www.SENSUSRx.com
Business Wire - Fri Nov 22, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced the launch of www.SENSUSRx.com. The website provides patients and physicians with a one-stop location for information about chronic pain such as painful diabetic neuropathy and the SENSUS(TM) Pain Management System. Traditional corporate website content such as investor relations and corporate governance is also accessible.
CSCO, GCVRZ, CDW and NURO added to NASDAQ Active Stock Watch List at EPR
ACCESSWIRE - Thu Nov 14, 9:15AM CST
New York, NY - (ACCESSWIRE) - 11/14/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Cisco Systems, Inc. (NASDAQ:CSCO), Sanofi (NASDAQ:GCVRZ), CDW Corporation (NASDAQ:CDW) and NeuroMetrix Inc. (NASDAQ:NURO)
Hot Stock: Neurometrix, Shares Gain 13.6% (NURO)
Comtex SmarTrend(R) - Wed Nov 13, 10:13AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 13.6% to $2.42 on 5.3x average daily volume. Thus far today, Neurometrix has traded 2.5 million shares, vs. average volume of 475,000 shares per day. The stock has outperformed the Dow (13.6% to the Dow's -0.4%) and outperformed the S&P 500 (13.6% to the S&P's -0.1%) during today's trading.
Healthcare Companies Report Financial Results, Scheduled Presentations, Marketing Clearance and Recognitions - Research Report on Air Methods, NeuroMetrix, Quintiles, Auxilium, and Cynosure
PR Newswire - Tue Nov 12, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Air Methods Corp. (NASDAQ: AIRM), NeuroMetrix Inc. (NASDAQ: NURO), Quintiles Transnational Holdings Inc. (NYSE: Q), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), and Cynosure, Inc. (NASDAQ: CYNO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
Business Wire - Thu Nov 07, 1:02PM CST
NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology & Diagnostics Forum at The Westin Grand Central, New York, NY on November 14, 2013. Dr. Gozani intends to provide an update on the Company's business activities with particular emphasis on its SENSUS(TM) pain management system for relief of chronic intractable pain, including pain associated with diabetic neuropathy.
SmallCapReview.com - Penny Stocks On The Move - NURO, MATR
M2 - Thu Nov 07, 11:35AM CST
NeuroMetrix (NASDAQ: NURO) Trading at $2.42, Up $0.50. Today reported business and financial highlights for the third quarter ended September 30, 2013.
